Key result
RAS inhibitor use linked to ~37% lower odds of muscle wasting in heart failure.
Why the study?
Experimental studies suggested RAS activation may negatively regulate muscle and bone mass, but this has not been analyzed in heart failure patients.
Observational (n=320)
No
Answers are grounded in this paper and cite their sources.
Should not yet change RASI prescribing for muscle preservation in HF; hypothesis-generating and requires prospective trials.
Aims Results of experimental studies have indicated the possibility of muscle and bone mass being negatively regulated by renin-angiotensin system (RAS) activation, but that possibility has not been analysed in patients with heart failure (HF). Methods and results Data for HF patients who received a dual-energy X-ray absorptiometry scan in our hospital were reviewed. Propensity scores for the use of RAS inhibitors (RASIs) were calculated using a multivariate logistic regression model to minimize selection bias. One hundred sixty pairs of patients were extracted. Plasma aldosterone concentration was significantly lower in the RASIs group than in the no-RASIs group (119 [IQR 71–185] vs. 94 [IQR 60–131] pg/mL, P = 0.003), confirming RAS inhibition in the RASIs group. Skeletal muscle mass index tended to be higher in the RASIs group than in the non-RASIs group (15.6 [IQR 14.0–17.2] vs. 15.0 [IQR 13.3–16.6] pg/mL, P = 0.065). The proportion of patients with muscle wasting, defined as appendicular skeletal muscle mass indexes of <7.00 and <5.40 kg/m2 for males and females, respectively, was significantly lower in the RASIs group than in the non-RASIs group (53% vs. 64%, P = 0.041). Multivariate logistic regression analysis showed that the no use of RASIs was associated with presence of muscle wasting independently of age, presence of diabetes, renal function, and severity of HF. Bone mineral densities and proportions of patients with osteoporosis were similar in the two groups. Conclusions Renin-angiotensin system inhibition is associated with a lower prevalence of muscle wasting in HF patients independently of established risk factors.
No takes yet. Share an insight, caveat, or question.
Katano et al. (2021) conducted an observational in Heart failure (n=320). Renin-angiotensin system inhibitors vs. No use of renin-angiotensin system inhibitors was evaluated on Presence of muscle wasting based on appendicular skeletal muscle mass index (OR 0.63, 95% CI 0.40-0.98, p=0.041). Renin-angiotensin system inhibitor use was associated with a lower prevalence of muscle wasting compared to non-use in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: